Mesotelioma peritoneal maligno. Nuestra experiencia con la triple terapia combinada: citorreducción, quimioterapia intraperitoneal perioperatoria e hipertermia

Portilla, Alberto Gómez; Cendoya, Ignació; Muriel, Jesús; Olabarría, Ignacio; Guede, Nera; Moraza, Nuria; Fernández, Elena; Lecea, C. Martínez de; Magrach, L.; Martín, E.; Romero, Erika; Aguado, Iker; Valdovinos, M.; Larrabide, Iñaki

doi:10.1016/s0009-739x(07)71268-x

Cited by 7 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The role of peri-operative systemic chemotherapy in addition to HIPEC with CRS was examined retro- Park et al [33] Loggie et al [112] Feldman et al [48] Costamagna et al [61] Brigand et al [6] 2006 Elias et al [60] Gómez Portilla et al [113] Hesdorffer et al [55] Passot et al [114] Chua et al [115] Blackham et al [49] Kluger et al [54] Cao et al [46] Alexander et al [47] Schaub et al [59] Wong et al [52] Deraco et al [37] Deraco et al [39] 2003 28 61% 70 NM Deraco et al [38] Deraco et al [40] Deraco et al [50] Baratti et al [20] Baratti et al [36] et al [54] reported on two-stage operative cytoreduction with intraperitoneal chemotherapy in 47 patients. Subjects initially underwent partial cytoreduction with peri-operative intraperitoneal therapy with single or dual regimens of cisplatin, gemcitabine, doxorubicin, or gamma interferon.…”

Section: Chemotherapy Agents Used For Hipecmentioning

confidence: 99%

Advances in the management of peritoneal mesothelioma

Ali

Huang

Takabe

2014

WJG

View full text Add to dashboard Cite

Malignant peritoneal mesothelioma (PM) is an infrequent disease which has historically been associated with a poor prognosis. Given its long latency period and non-specific symptomatology, a diagnosis of PM can be suggested by occupational exposure history, but ultimately relies heavily on imaging and diagnostic biopsy. Early treatment options including palliative operative debulking, intraperitoneal chemotherapy, and systemic chemotherapy have marginally improved the natural course of the disease with median survival being approximately one year. The advent of cytoreduction (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has dramatically improved survival outcomes with wide median survival estimates between 2.5 to 9 years; these studies however remain largely heterogeneous, with differing study populations, tumor biology, and specific treatment regimens. More recent investigations have explored extent of cytoreduction, repeated operative intervention, and choice of chemotherapy but have been unable to offer definitive conclusions. CRS and HIPEC remain morbid procedures with complication rates ranging between 30% to 46% in larger series. Accordingly, an increasing interest in identifying molecular targets and developing targeted therapies is emerging. Among such novel targets is sphingosine kinase 1 (SphK1) which regulates the production of sphingosine-1-phosphate, a biologically active lipid implicated in various cancers including malignant mesothelioma. The known action of specific SphK inhibitors may warrant further exploration in peritoneal disease.

show abstract

Section: Chemotherapy Agents Used For Hipecmentioning

confidence: 99%

Advances in the management of peritoneal mesothelioma

Ali

Huang

Takabe

2014

WJG

View full text Add to dashboard Cite

show abstract

“…Due to the low incidence of the disease, there are very few centers with large series of PM treated with CRS + HIPEC [ 12 , 13 ]. In Spain, we have only found a small series (7 patients) published in 2007 [ 14 ]. However, two essential multi-center studies [ 5 , 15 ], a meta-analysis [ 16 ] and multiple reviews have been published, among which it should be highlighted the recent PSOGI/EURACAN guideline [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Peritoneal Mesothelioma in a High Volume Peritoneal Surface Malignancies Unit

Pereira

Manzanedo

et al. 2023

JCM

View full text Add to dashboard Cite

Diffuse malignant peritoneal mesothelioma (PM) is a rare neoplasm, traditionally associated with a poor prognosis. There are other varieties of PM that are even less frequent and of uncertain malignancy. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has achieved prolonged survival in selected patients. The aim of this study is to analyze the patients with PM assessed in our center. Clinicopathological characteristics, diagnostic procedures and survival results from patients with PM appraised at our unit, according to the applied treatment, were analyzed. Seventeen patients were assessed between 2007 and 2019. Three cases had multicystic PM that were treated with complete CRS + HIPEC; all patients are alive and free of disease after a long follow-up. Three other cases had biphasic PM; a curative treatment could be performed in none of them, and their survival was minimal (<6 moths). Lastly, 11 cases with epithelioid PM were treated. Two cases were considered unresectable at laparoscopy (PCI 39); one of them had a long survival (67 months) with three iterative laparoscopic palliatives HIPECs for refractory ascites. The other nine cases were treated with curative CRS + HIPEC, with a median PCI of 14 (range 4–25), and a median overall survival (OS) of 58 months, with a 5-year OS of 47.4%. In conclusion, CRS + HIPEC, when possible, appears to be the optimal treatment for patients with PM. Knowledge of this therapeutic option is crucial, both to offer it to patients and to avoid delays in their referral to appropriate centers for treatment.

show abstract

Diffuse malignant peritoneal mesothelioma: Systematic review of clinical management and biological research

Baratti¹,

Kusamura²,

Deraco³

2011

Journal of Surgical Oncology

View full text Add to dashboard Cite

Diffuse malignant peritoneal mesothelioma (DMPM) is an uncommon and locally aggressive tumor with poor prognosis. Currently, no standard therapy is available. The biology of this disease is still poorly understood. We performed a systematic search of relevant studies on clinical management and biological research of DMPM. Trials were selected using a predetermined protocol. The current evidence suggests that cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy (PIC) results in improved survival. Biological understanding of DMPM is currently evolving.

show abstract

Mesotelioma peritoneal maligno. Nuestra experiencia con la triple terapia combinada: citorreducción, quimioterapia intraperitoneal perioperatoria e hipertermia

Cited by 7 publications

References 19 publications

Advances in the management of peritoneal mesothelioma

Advances in the management of peritoneal mesothelioma

Peritoneal Mesothelioma in a High Volume Peritoneal Surface Malignancies Unit

Diffuse malignant peritoneal mesothelioma: Systematic review of clinical management and biological research

Contact Info

Product

Resources

About